Skin Matters: A Review of Topical Treatments for Chronic Pain. Part Two: Treatments and Applications
Tóm tắt
Từ khóa
Tài liệu tham khảo
The Changing US Analgesia Market. 27 June 1994. Available from: http://www.thepharmaletter.com/file/55010/the-changing-us-analgesia-market.html . Accessed April 21, 2013.
Topical Analgesics. Pharmaceuticals: market research reports. Available from: http://www.marketresearch.com/Millennium-Research-Group-v648/Topical-Analgesics-6355096/ . Accessed April 21, 2013. Available by purchase only.
Ness TJ, Jones L, Smith H. Use of compounded topical analgesics-Results of an internet survey. Reg Anes Pain Med. 2002;27:309–12.
Gabler NB, Duan N, Vohra S, Kravitz RL. N-of-1 trials in the medical literature: a systematic review. Med Care. 2011;49:761–8.
Bloms-Funke P. Sodium Channels. In: Buschmann H, Christoph T, Friderichs E, Maul C, Sundermann B, editors. Analgesics: from chemistry and pharmacology to clinical application. Weinheim: Wiley; 2002. p. 297–331.
Eijkelkanp N, Linley JE, Baker MD, et al. Neurological perspectives on voltage-gated sodium channels. Brain. 2012;135:2585–612.
Yoemans DC, Levinson SR, Peters MC, et al. Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents. Hum Gene Ther. 2005;16:271–7.
Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain. 2007;131:243–57.
Galer BS. Topical Medications. In: Loeser JD, editor. Bonica’s Management of Pain. Philadelphia: Lippincott-Williams and Wilkins; 2001. p. 1736–41.
Attal N, Crucci G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153–69.
Rowbotham MC. Pharmacologic management of complex regional pain syndrome. Clin J Pain. 2006;22:425–9.
Gammaitoni AR, Alvarez NA. 24-h application of the lidocaine patch 5% for 3 consecutive days is safe and well tolerated in healthy adult men and women. Abstract PO6.20. Presented at the 54th Annual American Academy of Neurology Meeting, April 13–20, 2002, Denver.
Argoff C, Nicholson B, Moskowitz M, et al. Effectiveness of lidocaine patch 5% (Lidoderm®) in the treatment of low back pain. Presented at the 10th World Congress on Pain, August 17–22, 2002, San Diego.
Haroutiunian S, Drennan DA, Lipman AG. Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010;11:535–49.
Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106:151–8.
Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain. 2000;16:205–8.
Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48:332–8.
Herrmann DN, Barbano RL, Hart-Gouleau S, Pennella-Vaughan J, Dworkin RH. An open-label study of the lidocaine patch 5% in painful polyneuropathy. Pain Med. 2005;6:379–84.
Katz NP, Davis MW, Dworkin RH. Topical lidocaine patch produces a significant improvement in mean pain scores and pain relief in treated PHN patients: results of a multicenter open-label trial. J Pain. 2001;2:9–18.
Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin or a combination of both? A randomized, open clinical effectiveness study. Curr Med Res Opin. 2010;26:1607–19.
Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all Neuropathic Pain Qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the Neuropathic Pain Scale. Clin J Pain. 2002;18:297–301.
Geha PY, Baliki MN, Chialvo DR, Harden RN, Paice JA, Apkarian AV. Brain activity for spontaneous pain of post herpetic neuralgia and its modulation by lidocaine patch therapy. Pain. 2007;128:88–100.
López Ramírez E. Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5% patches. A radiation and oncology department experience. Support Care Cancer. 2013;21:1329–34.
Lycka BA, Watson CP, Nevin K, et al. EMLA® cream for the treatment of pain caused by post-herpetic neuralgia: a double-blind, placebo-controlled study. In: Proceedings of the Annual Meeting of the American Pain Society 1996;A111(abstract).
Attal N, Brasseur L, Chauvin M, Bouhassira D. Effects of single and repeated applications of a eutectic mixture of local anesthetics (EMLA®) cream on spontaneous and evoked pain in post-herpetic neuralgia. Pain. 1999;81:203–9.
Litman SJ, Vitkun SA, Poppers PJ. Use of EMLA® cream in the treatment of post-herpetic neuralgia. J Clin Anesth. 1996;8:54–7.
Fassoulaki A, Sarantopoulos C, Melemeni A, Hogan Q. EMLA reduces acute and chronic pain after breast surgery for cancer. Reg Anesth Pain Med. 2000;25:350–5.
Pereira J. Capsicum annuum. In: Carson J, editor. The elements of materia medica and therapeutics. 3rd ed. Philadelphia: Blanchard and Lea; 1854. p. 505–7.
Thresh JC. Isolation of capsaicin. Pharmaceut J Trans. 1876;6:941–7.
Backonja M, Malan P, Brady S. One-hour high concentration trans-capsaicin applications provide durable pain relief in initial and repeat treatment of postherpetic neuralgia. Presented at the 2004 Annual Scientific Meeting of the American Academy of Neurology, San Francisco.
Bley KR. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs. 2004;13:1445–56.
Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 agonist) therapy for pain relief: farewell or revival? Clin J Pain. 2008;24:142–54.
Kennedy WR, Vanhove GF, Lu SP, et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain. 2010;11:579–87.
Solcsanyi J. Turning up the heat on pain. TRPV1 receptors in pain and inflammation. In: Malmberg AB, Bley KR, eds. Birkhauser: Basel Switzerland; 2005.
ClinicalTrials.gov. A study to investigate the tolerability and effects on epidermal nerve fiber density of multiple low-concentrations of NGX-1998 in healthy volunteers. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00912262?term=capsaicin+and+liquid&rank=1 . Accessed April 20, 2013.
ClinicalTrials.gov. ALGRX 4975 in the treatment of patients with Morton’s neuroma. http://www.clinicaltrials.gov/ct2/show/NCT00130962?term=capsaicin+and+mortons+neuroma&rank=1 . NCT00130962. Accessed April 20, 2013.
Rains C, Bryson HM. Topical capsaicin: a review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy, and osteoarthritis. Drugs Aging. 1995;7:317–28.
Winocur E, Gavish A, Halachmi M, Eli I, Gazit E. Topical application of capsaicin for the treatment of localized pain in the temporomandibular joint area. J Orofac Pain. 2000;14:31–6.
Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004;24(328):991–6.
Robbins WR, Staats PS, Levine J, et al. Treatment of intractable pain with topical large-dose capsaicin: preliminary report. Anesth Analg. 1998;86:579–83.
Backonja MM, Malan TP, Vanhove GF. Tobias JK; C102/106 Study Group. NGX-4010, a high concentration patch, for the treatment of post herpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11:600–8.
Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of post herpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106–12.
Wallace M, Pappagallo M. Qutenza®: a capsaicin 8% patch for the management of post herpetic neuralgia. Expert Rev Neurother. 2011;11:15–27.
Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurol. 2008;70:2305–13.
Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107:490–502.
Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2013. doi: 10.1002/14651858.CD007393.pub3 .
Keitel W, Frerick H, Kuhn U, Schmidt U, Kuhlmann M, Bredehorst A. Capsicum pain plaster in chronic non-specific low back pain. Arzneimittelforschung. 2001;51:896–903.
Ortiz MI, Torres-López JE, Castañeda-Hernández G, Rosas R, Vidal-Cantú GC, Granados-Soto V. Pharmacological evidence for the activation of K+ channels by diclofenac. Eur J Pharmacol. 2002;438:85–91.
Barthel HR, Axford-Gatley RA. Topical non-steroidal anti-inflammatory drugs for osteoarthritis. Postgrad Med. 2010;122:98–106.
Mazieres B, Rouanet S, Velicy J, Scarsi C, Reiner V. Topical ketoprofen patch (100 mg) for the treatment of ankle sprain: a randomized, double-blind, placebo-controlled study. Am J Sports Med. 2005;33:515–23.
Mazieres B, Rouanet S, Guillon Y, Scarsi C, Reiner V. Topical ketoprofen patch in the treatment of tendonitis: a randomized, double blind, placebo controlled study. J Rheumatol. 2005;32:1563–70.
De Benedittis G, Lorenzetti A. Topical aspirin/diethyl ether mixture versus indomethacin and diclofenac/diethyl ether mixtures for acute herpetic neuralgia and postherpetic neuralgia: a double-blind crossover placebo-controlled study. Pain. 1996;65:45–51.
Brewer AR, McCarberg B, Argoff CE. Update on the use of topical NSAIDs for the treatment of soft tissue and musculoskeletal pain: a review of recent data and current treatment options. Phys Sports Med. 2010;38:62–70.
Stanos SP. Topical agents for the management of musculoskeletal pain. J Pain Symp Manag. 2007;33:342–55.
Baraf HS, Gloth FM, Barthel HR, Gold MS, Altman RD. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients; pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicenter trials. Drugs Aging. 2011;28:27–40.
Bruhlmann P, Michel BA. Topical diclofenac patch in patients with knee osteoarthritis: a randomized, double-blind, controlled clinical trial. Clin Exp Rheumatol. 2003;21:193–8.
Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized, controlled trial. J Rheumtol. 2004;31:2002–12.
Shainhouse JZ, Grierson LM, Naseer Z. A long-term open label study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee. Am J Ther. 2010;17:566–76.
Roth SH, Fuller P. Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis. J Pain Res. 2011;4:159–67.
Di Rienzo BL, Di Rienzo Businco A, D’Emilia M, Lauriello M, Coen Tirelli G. Topical versus systemic diclofenac in the treatment of temporo-mandibular joint dysfunction symptoms. Acta Otorhinolaryngol Ital. 2004;24:279–83.
Niethard FU, Gold MS, Solomon GS, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol. 2005;32:2384–92.
Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomized, controlled, 6 week trial (ISRCTN53366886). BMC Musculoskelet Disord. 2005;6:44.
Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomized controlled trials. BMJ. 2004;329:324–8.
Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDS for chronic musculoskeletal pain: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2004;5:28.
Myrer JW, Johnson AW, Mitchell UH, Measom GJ, Fellingham GW. Topical analgesic added to paraffin enhances paraffin bath treatment of individuals with hand osteoarthritis. Disab Rehab. 2011;33:467–74.
Predel HG, Koll R, Pabst H, et al. Diclofenac patch for topical treatment of acute impact injuries: a randomized, double blind, placebo controlled, multicenter study. Br J Sports Med. 2004;38:318–23.
Galer BS, Rowbotham M, Perander J, Devers A, Friedman E. Topical diclofenac patch significantly reduces pain associated with minor sports injuries: results of a randomized, double-blind, placebo-controlled, multicenter study. J Pain Symptom Manag. 2000;19:287–94.
Jenoure P, Segesser B, Lühti U, Gremion G. A trial with diclofenac HEP plaster as topical treatment in minor sports injuries. Drugs Exp Clin Res. 1993;19:125–31.
Machen J, Whitefield M. Efficacy of a proprietary ibuprofen gel in soft tissue injuries: a randomized, double-blind, placebo-controlled study. Intl J Clin Prac. 2002;56:102–6.
Whitefield M, O’Kane CJ, Anderson S. Comparative efficacy of a proprietary topical ibuprofen gel and oral ibuprofen in acute soft tissue injuries: a randomized, double-blind study. J Clin Pharm Ther. 2002;27:409–17.
Massey T, Derry S, Moore RA, McQuay HJ. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev. 2010. doi: 10.1002/14651858.CD007402.pub2 .
Marten M. Efficacy and tolerability of a topical NSAID patch (local action transcutaneous flurbiprofen) and oral diclofenac in the treatment of soft-tissue rheumatism. Clin Rheumatol. 1997;16:25–31.
Matthews P, Derry S, Moore RA, McQuay HJ. Topical rubefacients for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;8:CD007403.
Sandelin J, Harilainen A, Crone H, Hamberg P, Forsskåhl B, Tamelander G. Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double-blind study comparing eltenac with oral diclofenac and placebo gel. Scand J Rheumatol. 1997;26:287–92.
Dreiser RL, Tisne-Camus M. DHEP plasters as a topical treatment of knee osteoarthritis: a double-blind placebo-controlled study. Drugs Exp Clin Res. 1993;19:107–15.
Wilken M, Ineck JR, Rule AM. Chronic arthritis pain management with topical morphine:case series. J Pain Palliat Care Pharmacother. 2005;19:39–44.
Kolesnikov Y, Jain S, Wilson R, Pasternak GW. Peripheral kappa 1-opioid receptor-mediated analgesia in mice. Eur J Pharmacol. 1996;310:141–3.
Kolesnikov Y, Pasternak GW. Topical opioids in mice: analgesia and reversal of tolerance by a topical N-methyl-d-aspartate antagonist. J Pharmacol Exp Ther. 1999;290:247–52.
He L, Kim J, Ou C, McFadden W, van Rijn RM, Whistler JL. Methadone antinociception is dependent on peripheral opioid receptors. J Pain. 2009;10:369–79.
Zeppetella G, Paul J, Ribeiro MD. Analgesic efficacy of morphine applied topically to painful ulcers. J Pain Symptom Manag. 2003;25:555–8.
Bastami S, Frödin T, Ahlner J, Uppugunduri S. Topical morphine gel in the treatment of painful leg ulcers, a double-blind, placebo-controlled clinical trial: a pilot study. Int Wound J. 2012;9:419–27.
Cerchietti LC, Navigante AH, Bonomi MR, et al. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer. 2002;95:2230–6.
Nozaki-Taguchi N, Yaksh TL. Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist–loperamide. Anesthesiology. 1999;90:225–34.
Watterson G, Howard R, Goldman A. Peripheral opiates in inflammatory pain. Arch Dis Child. 2004;89:679–81.
Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153:1815–23.
Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manag. 2003;26:668–77.
Davis KD, Treede RD, Raja SN, Meyer RA, Campbell JN. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain. 1991;47:309–17.
McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol. 2000;49:574–9.
Lynch ME, Clark AJ, Sawynok J. A pilot study examining topical amitriptyline, ketamine, and a combination of both in the treatment of neuropathic pain. Clin J Pain. 2003;19:323–8.
Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain. 2008;24:51–5.
Lehman JS, Sciallis GF. Effective use of topical amitriptyline hydrochloride 2.5% and ketamine hydrochloride 0.5% for analgesia in refractory proctodynia. J Drugs Dermatol. 2008;7:887–9.
Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J Pain. 2005;6:644–9.
Uzaraga I, Gerbis B, Holwerda E, Gillis D, Wai E. Amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: a pilot study. Support Care Cancer. 2011;20:1515–24.
Quan D, Wellish M, Gilden DH. Topical ketamine treatment of postherpetic neuralgia. Neurology. 2003;60:1391–2.
Pöyhiä R, Vainio A. Topically administered ketamine reduces capsaicin-evoked mechanical hyperalgesia. Clin J Pain. 2006;22:32–6.
Quibell R, Prommer EE, Mihalyo M, Twycross R, Wilcock A. Ketamine. J Pain Symptom Manage. 2011;41:640–9.
Bernstein J, Phillips S, Group T. A new topical medication for the adjunctive relief of painful diabetic neuropathy and postherpetic neuralgia. J Pain. 2004;5(3 Suppl 1):82.
Slatkin NE, Rhiner M. Topical ketamine in the treatment of mucositis pain. Pain Med. 2003;4:298–303.
Reis GML, Duarte IDG. Baclofen, an agonist at peripheral GABAB receptors, induces antinociception via activation of TEA-sensitive potassium channels. Br J Pharmacol. 2006;149:733–9.
Nyirjesy P, Ahinoam LS, Leny M, Culhane JF. Topical amitriptyline-baclofen cream for the treatment of provoked vestibulodynia. J Low Gen Tract Dis. 2009;13:230–6.
Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011;19:833–41.
Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol. 2008;112:579–85.
Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64:274–83.
Perez RS, Zuurmond WW, Bezemer PD, et al. The treatment of complex regional pain syndrome type I with free radical scavengers: a randomized controlled study. Pain. 2003;102:297–307.
Zuurmond WW, Langendijk PN, Bezemer PD, Brink HE, de Lange JJ, van loenen AC. Treatment of acute reflex sympathetic dystrophy with DMSO 50% in a fatty cream. Acta Anaesthesiol Scand. 1996;40:364–7.
Gaspar M, Bovaira M, Carrera-Hueso FJ, Querol M, Jiménez A, Moreno L. Efficacy of a topical treatment protocol with dimethyl sulfoxide 50% in type 1 complex regional pain syndrome. Farm Hosp. 2012;36:385–91.
Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. 2008;139:541–50.
Phan NQ, Siepmann D, Gralow I, Ständer S. Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges. 2010;8:88–91.
Greenway FL, Frome BM, Engels TM 3rd, McLellan A. Temporary relief of postherpetic neuralgia pain with topical geranium oil. Am J Med. 2003;115:586–7.
Galeotti N, Di Cesare Mannelli L, Mazzanti G, Bartolini A, Ghelardini C. Menthol: a natural analgesic compound. Neurosci Lett. 2002;322:145–8.
Ray SB. Loperamide: a potential topical analgesic for the treatment of burn pain. J Burn Care Res. 2006;27:121–2.
Alessandri F, Lijoi D, Mistrangelo E, Nicoletti A, Crosa M, Ragni N. Topical diclofenac patch for postoperative wound pain in laparoscopic gynecologic surgery: a randomized study. J Minim Invasive Gynecol. 2006;13:195–200.
Kim KS, Nam YM. The analgesic effects of capsicum plaster at the Zusanli point after abdominal hysterectomy. Anesth Analg. 2006;103:709–13.
Kolesnikov YA, Chereshnev I, Pasternak GW. Analgesic synergy between topical lidocaine and topical opioids. J Pharmacol Exp Ther. 2000;295:546–51.
Paoloni JA, Murrell GA, Burch RM, Ang RY. Randomised, double-blind, placebo-controlled clinical trial of a new topical glyceryl trinitrate patch for chronic lateral epicondylosis. Br J Sports Med. 2009;43:299–302.
Paoloni JA, Murrell GA. Three-year followup study of topical glyceryl trinitrate treatment of chronic noninsertional Achilles tendinopathy. Foot Ankle Int. 2007;28:1064–8.
Carneiro PM, Rwanyuma LR, Mkony CA. A comparison of topical phenytoin with silverex in the treatment of superficial dermal burn wounds. Cent Afr J Med. 2002;48:105–8.
Carneiro PM, Nyawawa ET. Topical phenytoin versus EUSOL in the treatment of non-malignant chronic leg ulcers. East Afr Med J. 2003;80:124–9.
Pergolizzi JV, Pappagallo M, Raffa RB. Preliminary observations of a novel topical oil with analgesic properties for treatment of acute and chronic pain syndromes. Pain Pract. 2010;10:201–13.
Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind placebo-controlled trial of a topical crème containing glucosamine sulfate, chondroitin sulfate and camphor for osteoarthritis of the knee. J Rheumatol. 2003;30:523–8.
Van Haselen RA, Fisher PAG. A randomized controlled trial comparing topical piroxicam gel with a homeopathic gel in osteoarthritis of the knee. Rheumatology. 2000;39:714–9.
Gagnier JJ, van Tulder M, Berman B, Bombardier C. Herbal medicine for low back pain. Cochrane Database Syst Rev. 2006;9(2):CD004504.
Maier C, Baron R, Tölle TR, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain. 2010;150:439–50.
Wasner G, Kleinert A, Binder A, Schattschneider J, Baron R. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. J Neurol. 2005;252:677–86.
Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61:914–8.
Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573–81.
Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807–19.
Gustorff B, Hauer D, Thaler J, Seis A, Draxler J. Antihyperalgesic efficacy of 5% lidocaine medicated plaster in capsaicin and sunburn pain models—two randomized, double-blinded, placebo-controlled crossover trials in healthy volunteers. Exp Opin Pharmacother. 2011;12:2781–90.
World Congress of Pain, Milano 2012 Poster PH 113: Gustorff et al. Treatment of peripheral neuropathic pain with the capsaicin 8% patch: is quantitative sensory testing a useful tool to predict response of treatment? 2013.